title: T2N0M0 esophageal cancer.
abstract: OBJECTIVE
  The study objective was to develop a treatment algorithm for cT2N0M0 esophageal cancer by determining (1) errors in clinical staging and (2) consequences of overtreatment and undertreatment of incorrectly clinically staged patients.
  
  
  METHODS
  Of 742 clinically staged patients, 61 (8.2%) had cT2N0M0 cancer; 45 underwent surgery alone; 8 underwent surgery and postoperative adjuvant therapy; and 8 underwent induction therapy, then surgery. As reference, 31 of 666 patients (4.7%) who underwent surgery first had pT2N0M0 cancer and a 5-year survival of 61% +/- 9.3%. Referent values were calculated from 445 clinically staged patients who underwent surgery first. Unmatched and matched survival comparisons were made using the log-rank test.
  
  
  RESULTS
  Only 7 of 53 cT2N0M0 cancers treated with surgery first were pT2N0M0 (13% positive predictive value). Of incorrectly staged cT2N0M0 cancers (46/53), 29 (63%) were overstaged and 17 (37%) were understaged. Most overstaged cancers were pT1 (11 [38%] T1a and 15 [52%] T1b), and most understaged cancers were pN1 (13 [76%]). Matched overstaged patients treated by surgery alone (25/28) had a 5-year survival similar to that of patients with pTNM (69% +/- 9.8% vs 63% +/- 13%, P =.8). Understaged patients did better at 5 years than patients with pTNM if they had postoperative adjuvant therapy, not surgery alone (43% +/- 22% vs 10% +/- 9.5%, P = .17). Induction therapy decreased 5-year survival compared with all other treatment strategies (13% +/- 12% vs 52% +/- 7.4%, P =.05).
  
  
  CONCLUSIONS
  Patients with cT2N0M0 cancers should undergo surgery first with lymphadenectomy. Clinically understaged patients should receive postoperative adjuvant therapy. In the unlikely event that patients with cT2N0M0 cancers are found to have an uncommon pT2N0M0 cancer, they will have acceptable survival with surgery alone.
authors.affiliation: Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio 44195, USA. ricet@ccf.org
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Rice
authors.forename: David P
authors.initials: DP
authors.lastname: Mason
authors.forename: Sudish C
authors.initials: SC
authors.lastname: Murthy
authors.forename: Gregory
authors.initials: G
authors.lastname: Zuccaro
authors.forename: David J
authors.initials: DJ
authors.lastname: Adelstein
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Rybicki
authors.forename: Eugene H
authors.initials: EH
authors.lastname: Blackstone
mesh_terms: D000368:Aged; D000465:Algorithms; D001707:Biopsy, Needle; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016629:Esophagectomy / Q000379:methods; D004945:Esophagoscopy / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016896:Treatment Outcome